22:45 , Apr 29, 2019 |  BC Extra  |  Financial News

April 29 Quick Takes: Sirnaomics, Codiak, Cortexyme, Milestone, NextCure, Applied Therapeutics, Magenta

Sirnaomics closes $47M series C  RNAi therapeutics company Sirnaomics Inc. (Gaithersburg, Md.) raised $22 million in a series C2 round led by Hong Kong-based CR-CP Life Sciences Fund, closing out its series C round for...
02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
13:52 , Jun 29, 2017 |  BC Innovations  |  Translation in Brief

Tilt a flavin

A team from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and the University of Edinburgh has solved a problem that has stymied the development of kynurenine 3-monoxygenase (KMO) inhibitors -- the production of cytotoxic hydrogen peroxide -- and...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Clinical News

Arzerra ofatumumab: Additional Phase III data

Additional data from the open-label, international Phase III COMPLEMENT 2 trial in 365 patients with relapsed CLL showed that IV Arzerra plus fludarabine and cyclophosphamide led to a median PFS, the primary endpoint, of 28.9...
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

Arzerra ofatumumab: Phase III data

Top-line data from the open-label, international Phase III COMPLEMENT 2 trial in 365 patients with relapsed CLL showed that IV Arzerra plus fludarabine and cyclophosphamide met the primary endpoint of improving PFS vs. fludarabine and...
08:00 , Dec 15, 2014 |  BioCentury  |  Strategy

Momenta moving on

Data announced in October represent the first fruits of Momenta Pharmaceuticals Inc. 's novel drug pipeline, which will play a larger role in the company's strategy going forward as it steps back from complex generics....
08:00 , Nov 25, 2013 |  BC Week In Review  |  Clinical News

Lampalizumab: Additional Phase II data

Roche's Genentech Inc. unit disclosed the details of an exploratory biomarker from the single-blind Phase II MAHALO trial evaluating lampalizumab to treat GA associated with AMD. In August, data from 129 patients in MAHALO showed...
01:57 , Nov 19, 2013 |  BC Extra  |  Clinical News

Genentech details biomarkers for lampalizumab

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) disclosed the details of an exploratory biomarker for the company's lampalizumab ( RG7417 ), which is in development to treat geographic atrophy (GA), an advanced form of...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Arcturus Therapeutics, Marina Biotech deal

Marina sold its Unlocked Nucleobase Analog (UNA) patents for the development of RNAi therapeutics to Arcturus. Marina retains a non-exclusive license to the technology. UNAs are acyclic ribonucleoside analogs in which the bond between the...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Company News

Marina Biotech, Tekmira Pharmaceuticals Inc. deal

Marina Biotech granted Tekmira a non-exclusive, worldwide license to develop and commercialize RNAi therapeutics using Marina Biotech's Unlocked Nucleobase Analog (UNA) technology for undisclosed indications. Marina Biotech will receive an undisclosed upfront payment and is...